In this activity, Mary McGorray, MD interviews Sharon Bergeron, RN, BSN, CPON about how hematology/oncology nurses can identify silent inactivation of asparaginase therapy and other AEs including hyperammonemia, and pancreatitis, thrombosis/hemorrhage, and hepatotoxicity.

In this activity, Mary McGorray, MD interviews Sharon Bergeron, RN, BSN, CPON about her experience treating patients with asparaginase in multi-agent chemotherapeutic regimens. In Part 2, Sharon explains how nursing observations during infusions, and utilizing therapeutic drug monitoring are key in facilitating ALL and LBL disease-response and clinical outcomes.

In this activity, Mary McGorray, MD interviews Sharon Bergeron, RN, BSN, CPON about her experience treating patients with asparaginase in multi-agent chemotherapeutic regimens. Part 1 describes the role and utility of asparaginase in the treatment of patients living with ALL and LBL.